Company

About us

Scintomics Molecular, Applied Theranostics Technologies (ATT) is a growing player in the radiopharmaceutical business with a particular strategic emphasis on providing unrestricted supply and support of proprietary and innovative tracer technology and non-IP protected precursors, such as PSMA I&T (patent protected in several EU countries and Australia) and next generation PSMA inhibitors for radioligand therapy

The well-known GRP Module Series became part of ATT in April when ATT took over the Module business from its Parent company Scintomics, which has been selling and installing fully automated production systems for established radio-pharmaceuticals in clinical facilities around the world since 2006.

0
+
Happy Clients
0
Years In Business
0
Countries
0
Cups of Coffee

ATT Worldwide

Our Distributor Network

ATT Worldwide

Customer Worldwide

Our Scintomics/att History

2006

Founded by Prof. H. J. Wester (TUM)

Founded by Prof. H. J. Wester (TUM)

Start of:

Hotbox series & Gallelut (still running at several customer sites)

2010

Start of:

Start of:

GRP Modules for GMP production and radiopharmaceutical research (in the meantime over 200 installed systems worldwide)

Innovative tracer techniques and Radiopharmaceuticals for Imaging and Therapy, (IP protected in several countries)

2018

Scintomics Molecular, att GmbH founded by Scintomics GmbH

New portfolio with cassettes, consumables and precursors, such as PSMA I&T (patent protected in several EU countries and Australia) and next generation PSMA inhibitors for radioligand therapy.

2020

att takes over Module Business from Scintomics

att takes over Module Business from Scintomics

Start of:

new siGRP-Module:

for production of the two SiFA-based radiopharmaceuticals [F-18]siPSMA and [F-18]SiFAlin-TATE – ready to compete with Ga-68 !

Our Gallery

Scintomics

Scintomics, a privately held company based near Munich/Germany, is committed to targeted theranostics and corresponding radiopharmaceutical technologies. Its strong focus towards personalized cancer care is reflected by an exceptional and continuously growing portfolio of innovative tracer technologies and the clinical development of Theranostic through subsidiaries, joint ventures and alliances.

 

Its subsidiary Scintomics Molecular, Applied Theranostics technologies continues Scintomics ́ radiopharmaceutical business segment in an independent manner with a particular strategic emphasis on providing unrestricted supply and support of Scintomics proprietary and innovative tracer technology and non-IP protected precursors as well as the more than 15 year experience in Synthesis Modules.

PentixaPharm

PentixaPharm is a young radiopharmaceutical company committed to developing the innovative theranostic pair PentixaFor and PentixaTher. These two-small peptide-based radiopharmaceuticals specifically target the CXCR4-receptor expressed in most fast progressing diseases such as hematological and solid cancers as well as cardiovascular malignancies. The current development program comprises a solid preclinical and manufacturing development package as well as an advanced diagnostic trial with PentixaFor and an early therapeutic trial with PentixaTher.